Alphamab Oncology is a HKEX-listed commercial-stage biotechnology company committed to the research and development of innovative biopharmaceuticals for cancer treatment. The company currently has one product on the market, one under BLA review, several in various stages of clinical development and more in pre-clinical stage.

AlphaMab has established cutting-edge platforms for ADC development, such as the glycan-specific conjugation platform, proprietary linker-payload platform, and dual-payload platform, which enable the generation of globally competitive ADC assets with enhanced efficacy and safety profiles.

Alphamab is actively looking for partnership opportunities for its innovative bi-specific antibodies and ADC programs and proprietary glycan-specific dual-payload platform.